News | May 07, 2026
Eli Lilly unveils $4.5 bn Indiana expansion
The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies
The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
The platform offers personalised recovery plans, AI-driven movement tracking, and access to certified physiotherapists for more than 250 conditions
The private funding rose 38% amid growing international collaborations and CDMO demand
Report highlights growing confidence in digitalisation and AI, even as healthcare leaders remain concerned about workforce gaps, cybersecurity, and data readiness
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
Acquisition of medical equipment distributor aims to strengthen European commercial operations and optimise distribution costs
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
